

Testimony of  
**Mr. Dennis Archer**  
President-elect  
American Bar Association

March 5, 2003

Mr. Chairman and members of the Committee:

My name is Dennis Archer and I am here today at the request of our ABA President Alfred P. Carlton, Jr. on behalf of the American Bar Association, the world's largest voluntary professional organization with more than 410,000 members. I appear before you today in my capacity as the President-Elect of the ABA. I am pleased to be with you today and present you the views of the ABA regarding asbestos litigation.

#### I. Introduction

Today the United States faces an asbestos crisis that has gotten progressively worse over the past 20 years and is taking its toll on those who are sick with asbestos-related diseases and their families and on the court system. More than 200,000 claims are presently clogging the court system and tens of thousands of new claims are filed each year. Truly sick individuals are facing lengthy delays due to clogged court dockets. Funds that are needed to compensate persons who are sick now or who will become seriously ill from asbestos later are in danger of being dissipated due to claims by those who are not sick and may never become sick. The flood of claims from those who are asymptomatic is also harming current employees, retirees and shareholders of defendant corporations.

The ABA has long been concerned about the situation regarding asbestos claims. In February 1983, the ABA reaffirmed its opposition to broad federal product liability legislation. However, in the same resolution, (hereinafter identified as the February 1983 ABA policy), the ABA adopted a policy in support of narrowly drawn federal legislation in two discrete areas of product liability law. One of those areas was victim compensation for certain occupational diseases such as asbestosis.

The February 1983 ABA policy supported federal legislation that addresses the issues of liability and damages with respect to claims for damages against manufacturers by those who contract an occupational disease (such as asbestosis) when: a) there is a long latency period between exposure to the product and manifestation of the disease; b) the number of such claims and the liability for such damages in fact threaten the solvency of a significant number of manufacturers engaged in interstate commerce; and c) the number of such claims have become clearly excessive burdens upon the state and federal judicial systems.

In its report, the Committee that sponsored the February 1983 policy stated that it "believes that the current social problem presented by occupational latent diseases, such as asbestosis, is unique and has been a catastrophic phenomenon on a national

scale to asbestos workers and to the asbestos industry. While this Committee is reluctant to recommend federal intervention in the tort liability and common law systems of the several states, the Committee believes that the unique national scope and magnitude of the problems for adequate compensation to injured parties and liability for occupational latent diseases as they affect the financial stability of the specific industry, such as asbestos, warrants attention at the federal level. The Committee also believes that federal attention to such a unique and urgent national problem is neither premature nor precipitous, and would not result in harmful violation of the inherent values of this country's common law tort liability systems of the several states."

In 1991 the Judicial Conference Ad Hoc Committee on Asbestos Litigation appointed by Chief Justice Rehnquist found that "the situation has reached critical dimensions and is getting worse." The Ad Hoc Committee "recognize[d] that virtually all of the issues relating to a so-called 'national solution' are primarily matters of policy for the Congress" and stated that it "firmly believes that the ultimate solution should be legislation recognizing the national proportions of the problem..." U.S. Judicial Conference Ad Hoc Committee on Asbestos Litigation, p.2 (March 1991) (emphasis added).

In the continued absence of legislative action, some courts and parties attempted to craft creative solutions to the growing body of asbestos claims, including litigation class actions, settlement class actions, mass trial consolidations, joint defense claims handling organizations, and "global" settlement negotiations. None succeeded. Class actions failed because the factual disparity among the various claims and the disparate interests of present and future claimants precluded proper treatment under Federal Rules of Civil Procedure 23. The Supreme Court in 1997 and 1999 reviewed and struck down two proposed class action settlements known as the Amchem settlement and the Ortiz settlement. In both cases, however, the Supreme Court called upon Congress to correct the problem. Justice Ginsberg delivered the opinion for the Court in *Amchem Products, Inc. v. Windsor*, 521 U.S. 591, 117 S.Ct. 2231, 138 L.Ed. 2d 689 (1997), in which she noted that the Judicial Conference had urged Congress to act on the situation and "no Congressional response has emerged." In *Ortiz v. Fibreboard Corp.*, 527 U.S. 815, 119 S. Ct. 2295, 144 L.Ed. 2d 715 (1999), Justice Souter delivered the opinion for the Court and said "this case is a class action prompted by the elephantine mass of asbestos cases, and our discussion in *Amchem* will suffice to show how this litigation defies customary judicial administration and calls for national legislation" 527 U.S. at 821 (emphasis added). Chief Justice Rehnquist's concurring opinion stated that asbestos litigation "cries out for a legislative solution" 527 U.S. at 865.

Mass consolidations, at least in the eyes of some courts, suffered similar shortcomings. See, e.g., *Cimino v. Raymark Industries, Inc.*, 151 F.3d 297, 320-21 (5th Cir. 1998); *Malcolm v. National Gypsum Co.*, 995 F.2d 346, 350-353 (2d Cir.1993); *Cain v. Armstrong World Industries*, 785 F.Supp. 1448, 1454-56 (S.D.Ala. 1992). Joint defense claims handling organizations dissolved over various strategic and liability share issues, as did "global" settlement negotiations.

The February 1983 policy is silent as to what type of federal legislation might be appropriate in the area of asbestos. In the intervening years, the situation has become

much worse and we believe must be addressed. Until last month, no subsequent ABA policy was adopted to address asbestos litigation or legislation.

In November 2002, at my request, the ABA created a Commission on Asbestos Litigation to bring a recommendation to the House of Delegates at its February 2003 meeting concerning widely reported and longstanding problems in asbestos litigation. The recommendation was to address dual concerns: 1) protecting the right of claimants with impairing asbestos-related injuries to obtain fair compensation efficiently in the tort system, and 2) preventing scarce judicial and party resources from being misdirected by a flood of premature claims by individuals who have been exposed to asbestos but do not have, and may never get, any functional impairment from asbestos-related disease.

In establishing a commission to develop policy in the area, the ABA was most concerned about ensuring that those who become sick from asbestos-related diseases will receive reasonable and fair compensation for themselves and their families. The ABA is concerned that funds are being dissipated by payments to those who are not now sick and may never be sick with asbestos-related diseases, and the costs associated with administering those claims. A number of factors go into why those who are not yet sick file a claim. We acknowledge that those who file a claim often do so when they are not yet sick in order to file within the time prescribed by a statute of limitations. Others do so because they fear that, if companies go bankrupt by waiting, these claimants may not be compensated. These people often settle for a comparatively small amount of money in return for a complete release. Most never get sick, but those who do become sick are often precluded from the compensation they need, at the time they really need it.

Over the past 20 years, the problems associated with the tremendous volume of cases and the national scope of the problem resulted in increasingly urgent calls for federal legislation to address the problem. Recently, the concept of federal legislation to: 1) allow those with non-malignant asbestos-related diseases to file a cause of action only if they meet specific medical criteria; and 2) toll all applicable statutes of limitations until those criteria are met has come to the radar screen as a possibility of dealing with the crisis at hand. At this time there is no national Standard to separate claimants who are not sick from those who are sick from asbestos.

The ABA believes that Congress should enact a Standard like the one developed by the ABA Commission or a similar appropriate Standard that would: (a) identify non-malignant claims that are entitled to compensation and defer those that do not currently belong in the courts, and (b) ensure that state and federal statutes of limitations do not run against individuals who do not yet (and may never) meet the medical criteria in the Standard. Such a Standard should deal only with non-malignant claims and not in any way deal with claims for asbestos-related cancers or malignancies.

The ABA adopted policy last month, attached as "Appendix A," does just that. Attached as "Appendix B" is a medically sound "Standard for Non-Malignant Asbestos-Related Disease Claims" that the ABA has developed. The ABA developed the Standard with the

goal of ensuring that no one who should be permitted to file a claim would be precluded from filing one. We have attempted to be inclusive, while recognizing that no real progress could be made without establishing objective medical criteria for presently compensable claims.

While this issue is indeed complex and does indeed have important consequences, it is not new. Lawyers, public advocacy groups and think tanks have been studying the issue for more than two decades. The ABA Commission members reviewed the extensive list of studies, statements and testimonies that have resulted from this effort and held consultations with leading medical experts on pulmonary function. Commission members worked very hard on this matter because they are truly concerned about those who have become sick due to exposure to asbestos. Their hard work produced, in my view and in the view of the 70% of the members of the ABA House of Delegates, a fair standard.

We believe this Standard or appropriate similar standards should be considered by Congress.

If legislation along these lines is not enacted, the assets of the defendants will be consumed by people who are not sick, leaving little or nothing for those who become sick in the years ahead. In addition, companies continuously being sued by those not impaired are likely to become less capable of earning money to pay claims. Analysts are now looking at footnotes in the annual reports of such companies to determine asbestos liability, and the financial ratings of these companies are being impacted negatively. If the present course continues, jobs and economic value will be lost and even more companies will be pushed into bankruptcy—causing further delays and reduced compensation to the very sick.

## II. Background

Asbestos litigation is not a new phenomenon. It is the tragic legacy of extensive industrial use of asbestos in the workplace, predominantly from the 1930s to the early 1970s. Significant numbers of industrial workers began developing disabling, and sometimes fatal, asbestos-related diseases decades later (a delay attributable to the long latency between exposure and manifestation of disease). They brought suit against a relatively small number of former manufacturers of asbestos-containing industrial insulation products.

By the 1980s, what had once been a series of isolated cases turned into a steady flow. Claimants began regularly obtaining significant awards. In 1982, Johns-Manville Corporation -- the single largest supplier of asbestos-containing insulation products in the U.S. and the primary target of the early claims -- declared bankruptcy due to the burden of the asbestos litigation. At that point, it had approximately 16,000 pending claims. By comparison, today it is common for some defendants to have more than 100,000 cases pending.

The asbestos litigation paused only briefly, if at all, as a result of the Manville bankruptcy. Heavily exposed industrial workers continued to get sick from asbestos-related diseases and to bring claims in the tort system throughout the 1980s and into the 1990s. Asbestos dockets in certain jurisdictions swelled. Several other former manufacturers of asbestos-containing insulation declared bankruptcy (e.g., Unarco, Eagle-Picher, Raybestos Manhattan, Celotex).

Despite the failure of efforts to find a new solution to the asbestos litigation, the tort system appeared to be relatively stable in the early 1990s. The flow of new claims was substantial (RAND estimates it was 15,000 to 20,000 per year), but fairly predictable. (Asbestos Litigation Costs and Compensation, An Interim Report, RAND Institute for Civil Justice, 2002, hereinafter the "RAND report"). More importantly, it appeared that by the mid 1990s there was a downward trend in new filings, reflecting the fact that the period of most intensive industrial use of asbestos had drifted further into the past and the occurrence of disabling non-malignant diseases was falling in corresponding fashion.

In retrospect, however, it is clear that a countervailing trend was emerging and accelerating in the 1990s: for profit litigation screenings began systematically generating tens of thousands of new non-malignant claims each year by individuals who had some degree of occupational asbestos exposure, but did not have, and probably would never get an impairing asbestos-related disease. These individuals may or may not have markings on lung x-rays "consistent with" exposure to asbestos (and dozens of other possible causes) but do not, and may never, experience any symptoms of asbestos disease or develop any asbestos-related conditions that would impair or affect their life or daily functions.

Asbestos exposure can affect the body in a number of ways. It can cause mesothelioma, a cancer of the exterior lining of the lung and peritoneum. It can also cause cancer inside the lung. Although there is an ongoing debate about the issue, some believe that it can cause cancer at other sites in the body.

Asbestos exposure can also cause non-malignant pulmonary disease. Asbestosis is a fibrosis (scarring) of tissue inside the lung, particularly in the walls surrounding the alveolar spaces at the end of the airways. Significant fibrosis in this area reduces the elasticity of the lung and interferes with the lung's ability to oxygenate the blood. Asbestotic lungs are characterized by reduced capacity, i.e., they can process only a reduced volume of air compared to normal lungs. Workers who suffer from significant asbestosis generally have shortness of breath on exertion.

Asbestosis can be a progressive disease. In its milder forms, it may not cause any symptoms. It may or may not progress to the point of causing functional impairment detectable on objective pulmonary function tests.

Asbestos exposure may also cause non-malignant changes in the pleura, the tissue that lines the outside of the lung and the inside of the rib cage. The purpose of the pleura is to facilitate the smooth, constant movement of the lungs as they expand and contract.

Asbestos exposure can cause circumscribed thickening of pleural tissue (called “pleural plaques”) as well as diffuse pleural thickening. Ordinarily, these conditions -- which occur outside the lung -- do not result in any functional impairment. Significant diffuse pleural thickening, however, can restrict the ability of the lung to expand and may result in objective impairment that can be identified by pulmonary function testing.

While pleural plaques and diffuse pleural thickening involve the same tissue that is involved in the malignant disease mesothelioma, they are different physiological processes. Pleural plaques and pleural thickening do not become or lead to mesothelioma. Mesothelioma incidence is a function of exposure and individual susceptibility, not the presence or absence of non-malignant pleural changes.

By virtually all accounts, contemporary asbestos litigation is no longer driven solely, or even primarily, by the occurrence of disabling asbestos-related diseases. Asbestos-related cancer and impairing asbestosis continue to occur, but they represent a small fraction of annual new filings. A recent RAND report noted that some studies claim that somewhere between two-thirds and 90% of new claims are now brought by individuals who have radiographically detectable changes in their lungs that are “consistent with” asbestos-related disease (and with dozens of other causes), but have no demonstrated functional impairment from those changes: The RAND report concluded that, “it appears that a large and growing proportion of the claims entering the system in recent years were submitted by individuals who have not incurred an injury that affects their ability to perform activities of daily life.” RAND report at pg. vi; and, pg. 20, 21.

Currently, lawyers are doing what they think is best for their clients. The manner in which the statutes of limitations operate under some states’ laws is a major factor in generating numerous claims by claimants who are asymptomatic or without functional impairment. The ABA wants to improve the administration of justice by ensuring that only symptomatic persons file claims and that the statute of limitations is tolled for those who are not yet sick. Thus, the courts and the lawyers will be better able to handle these cases.

A number of states have expressly adopted a “two disease” rule for asbestos-related claims. Under this rule, a claimant who suffers from asbestosis must timely file a claim for that disease, but is not automatically barred from bringing a separate claim many years later should he or she develop an asbestos-related cancer. However, even states that have adopted the two-disease rule have found that it has not stopped the high levels of filings by asymptomatic plaintiffs.

The result of the legal dilemma created by screenings and statutes of limitations is the wholesale filing of premature non-impairment claims. The statistics are startling. In 2001, the Manville Trust received over 90,000 new claims -- more than in any prior year and nearly six times the total number of claims pending against Manville when it declared bankruptcy twenty years before. Between 2000 and 2002, the Trust received more than

200,000 claims. The Trust has reported that more than 90% of the claims allege only non-malignant changes.

The experience of the Manville Trust is not unique. According to the RAND report, there has been a substantial increase in annual new filings for all defendants since the mid 1990s, and the increase is almost entirely attributable to non-malignancy filings. The vast majority of those non-malignancy claims, RAND reports, do not involve functional, objectively measurable impairment from asbestos-related disease.

The financial impact of this flood of non-impairment claims has been profound. According to the RAND report, more than sixty otherwise financially viable companies have gone bankrupt due to asbestos-related liabilities, over twenty in the last two years. None has claimed an inability to pay fair compensation to truly sick claimants. Virtually all point to the same problem: tens of thousands of non-impairment claims filed each year, with no end in sight.

Nobel Laureate Professor Joseph Stiglitz of Columbia University recently issued a report, commissioned by the American Insurance Association, that calculates the economic impact of these bankruptcies on the employees of the bankrupt companies. He estimates that 60,000 workers have lost their jobs when their companies went bankrupt as a result of asbestos-related liabilities. (The RAND report estimates job losses at approximately 128,000.) Stiglitz concludes that “[e]ach displaced worker at the bankrupt firms will lose, on average, an estimated \$25,000 to \$50,000 in wages over his or her career” and every worker will suffer “roughly \$8,300 in pension losses, which represent[s], on average, a roughly twenty five percent reduction in the value of the 401(k) account.” Joseph E. Stiglitz, Jonathan M. Orszag, & Peter R. Orszag, “The Impact of Asbestos Liabilities on Workers in Bankrupt Firms” (December 2002) at 3.

The direct costs of asbestos-related bankruptcies can be very substantial. Owens Corning, for example, recently disclosed that, in approximately two years, it has incurred \$200 million in legal and consulting fees. These costs directly reduce the funds available to pay claimants.

Bankruptcy has not helped seriously ill asbestos claimants, either. Claims payments stop immediately when bankruptcy is declared and do not resume for several years, and then at significantly reduced values. The Manville Trust is currently paying only five cents on the dollar to claimants. Due to the flood of non-impairment claims, the Trust reports that, over the last five years, it has paid more money to claimants who describe themselves as unimpaired than it has to mesothelioma claimants.

Once a lawsuit is filed, unimpaired claimants may choose to resolve their claims for minimal values, executing a complete release. For the vast majority who never develop a disabling asbestos-related disease, the money is arguably a windfall. For those who later develop mesothelioma, the filing and resolution of a premature claim and execution of a full release can become a haunting mistake.

It is for these reasons, as well as concerns over the availability of fair compensation for seriously ill asbestos disease victims, that many disparate voices have joined in the call for change. The flood of non-impairment claims generated by litigation screenings crowd active litigation dockets, lengthening delays in the disposition of mesothelioma and other serious injury claims.

### III. Discussion of the Standard referred to in the ABA's resolution that was developed by the ABA's Commission on Asbestos Litigation

The bulk of the ABA Commission on Asbestos Litigation's work focused on developing objective medical criteria that identify individuals with non-malignant asbestos-related disease causing functional impairment and separate out cases where either the individual has no functional impairment or is impaired solely by some other cause, such as asthma, emphysema or smoking.

Similar criteria have been in use in many areas of the asbestos litigation for years. Several courts, including those in New York, Boston, Chicago and Baltimore, have used medical criteria to place unimpaired claimants on "pleural registries" or inactive dockets that keep such cases dormant until the claimant becomes impaired. Some private settlement agreements between defendants and plaintiffs' firms use such criteria, and courts have found such criteria to be fair. However, rather than adopt existing criteria from some other source, the Commission developed its criteria only after interviewing pulmonologists and occupational medicine specialists, including doctors who had testified for both plaintiffs and defendants in asbestos litigation. As a result, while the Commission's recommended criteria are similar to many of those already in use, it is not identical to any of them.

A diagnosis of asbestos-related pleural disease, and particularly asbestosis, requires assessment of a number of factors, including the review of chest x-rays, pulmonary function tests, latency, and the taking of a complete occupational, exposure, medical and smoking history. Because many symptoms and findings are not specific to asbestos-related disease, this approach is necessary to enable a physician to exclude other more probable causes for various findings. This then enables the physician to support a conclusion that the patient's medical condition is the result of asbestos exposure. These types of requirements are typical for assessment of disability or impairment under various legislative and regulatory systems, including Social Security, the Federal Employees Compensation Act (FECA), and state worker compensation programs.

As a result, the Commission's medical criteria in the recommended Standard include several elements. Doctors basically agree that diagnosis of asbestosis that causes functional impairment requires several components, including (1) a history of occupational and other asbestos exposure, as well as a complete medical and smoking history, (2) a latency period of at least 15 years between initial asbestos exposure and the onset of disease, (3) an x-ray that suggests the presence of asbestosis, and (4)

pulmonary function test (“PFT”) results that establish abnormally low lung function and rule out the probability that the impairment was caused solely by something other than asbestos. Each of these requirements is incorporated into the Commission’s recommended Standard, but certain key issues are discussed more fully below.

In drafting this Standard, the Commission attempted to achieve its goal of deferring only those claims involving individuals who are not impaired as a result of exposure to asbestos. As will be seen below, in several instances the Standard adopts less restrictive alternatives than some physicians recommended. The effect of this may be to allow claims that do not really belong in the tort system, but the ABA prefers to take that approach rather than to unfairly exclude any significant number of deserving claims.

If Congress were to adopt a weaker Standard it would render it ineffective in achieving the goal of ending the flood of premature claims that clog the courts and sap resources from the system and from truly sick claimants. Thus, the ABA would support enactment of either this Standard or an appropriate similar Standard.

#### A. X-ray Standards

A positive x-ray reading is almost always viewed as a necessary component of the diagnosis of asbestosis. It is not by itself a finding of functional impairment or a diagnosis of asbestos-related disease. X-ray readings have governing standards, but often depend upon the judgment of the individual doing the reading.

1. ILO Readings: The International Labor Office, in an attempt to standardize the classification of chest x-rays involving pneumoconiosis, created the ILO scale as a means of grading dust-related changes on chest x-rays. The ILO scale attempts to gauge the severity of the irregularities found by the reader, using a scale from 0 (normal) to 3. A grade of 0/0 would indicate a normal lung. A grade of 1/0 indicates that the reader found evidence of minimal lung irregularities – the “1” – but also considered whether the x-ray should be read as normal, or “0.” A reading of 1/1 means that the reader found clear evidence of minimal lung irregularities, and is a stronger finding than a 1/0. A 2/1 or greater indicates more extensive lung abnormalities.

The American Thoracic Society (ATS) has stated that a 1/1 reading is an important factor in the diagnosis of asbestosis, but allows a diagnosis of mild asbestosis based upon a chest x-ray reading graded 1/0 in the presence of other confirming diagnostic findings. However, some settlement agreements and court orders creating “inactive dockets” have used 1/1 as an appropriate standard.

The Commission elected to incorporate a 1/0 standard into its medical criteria, for several reasons. First, the Commission intended that the standards not be unfairly exclusionary. Second, those who over-read x-rays as 1/0 for litigation purposes might just as easily over-read them as 1/1 if necessary to meet a medical standard. Finally, properly administered PFT’s (discussed below) are the most important screening tool to

determine significant asbestos-related functional impairment.

2. B readers: The minimum standard recommended by the Commission requires a positive chest x-ray finding by a NIOSH certified B reader. A B reader is a person, usually but not necessarily a doctor, who has passed the tests necessary for certification that he or she is qualified to read x-rays according to ILO standards. The requirement of a B reading in the proposed medical criteria reflects the Commission's attempt to create a uniform standard for the diagnosis of nonmalignant asbestos-related disease. The Commission also notes that B readings are already prevalent in asbestos litigation. The Commission acknowledges that many physicians who are not certified B readers are still qualified to read chest x-rays for the presence or absence of asbestos-related disease, but the Standard adopts the B reader requirement in an attempt to obtain uniform standards.

3. CT Scans: A number of medical experts consulted by the Commission felt that both computer tomography scans and high-resolution computer tomography scans (CT & HRCT) can be useful diagnostic tools in distinguishing asbestosis and asbestos-related pleural disease from other chest abnormalities. However, these doctors acknowledged that no objective standard analogous to the ILO B reading scale for grading chest x-rays exists for the grading of CT and HRCT Scans. The lack of applicable standards compelled the Commission to require a positive B reading of a chest x-ray as the minimum radiologic diagnostic standard, rather than positive CT or HRCT Scans.

#### B. Pulmonary Function Tests

The Commission's proposed Standard requires that a claimant meet certain requirements on pulmonary function tests. The PFTs in the Standard demonstrate functional impairment, and also demonstrate that the impairment is of the type (restrictive impairment) that can be caused by asbestos exposure.

1. Testing methodology: It is generally accepted that pulmonary function testing provides the primary objective basis for assessment of functional impairment. However, the results of such testing can be affected by patient effort as well as technical deficiencies. Many of the doctors who met with the Commission believe that adherence to test quality standards has eroded in the asbestos litigation arena.

The American Thoracic Society in their 1991 and 1994 Official Statements published technical standards for pulmonary function testing, including equipment, methods of calibration, technique and interpretation. Virtually all of the physicians consulted by the Commission agreed that PFT's used for purposes of satisfying the medical criteria should meet the ATS technical criteria. This includes attachment of all test results and appropriately labeled spirometric tracings. One physician who met with the Commission, who has never testified in asbestos litigation, has evaluated tens of thousands of pulmonary function test results. He believes that ATS technical criteria are met in only 1% of the cases he has seen arising from litigation; in contrast, pulmonary function results outside the litigation/claims arena meet ATS technical criteria 90% of the time.

The Commission strongly believes that PFT's must be conducted according to ATS testing standards to be reliable for use in medical criteria. In addition, to ensure compliance with quality standards, the Standard requires that all PFT reports be included as attachments. This should not be an undue burden on claimants since, under the proposed Standard, they are required to have had these tests prior to filing their claim.

2. Impairment measures: The proposed criteria include several measures of impairment. These are discussed below.

**Forced Vital Capacity:** Asbestosis can cause restrictive lung disease. The scarring of the lung caused by asbestosis reduces the capacity of the lungs to retain and expel air. This reduced volume can be measured by Forced Vital Capacity (FVC), the amount of air exhaled after a deep breath with maximum force during a standard pulmonary function test. The proposed criteria require that to demonstrate impairment, a claimant demonstrate Forced Vital Capacity "below the lower limit of normal." The Commission considered whether to select a particular standard to use as "normal," but elected not to do so in order to allow medical science to continue to develop in this area. The Commission does note, however, that some standards suggest the use of racial adjustment factors in determining the measure of lung capacity. The Commission expressly intends that racial adjustment factors not be used in applying its medical criteria. Omitting these racial adjustments will have the effect of qualifying additional claims, rather than excluding claims, but is consistent with fairness and the Commission's desire that its standard be inclusive rather than overly exclusive.

**FEV1/FVC ratio:** It is critical to distinguish restrictive lung disease, which can be caused by asbestos, from obstructive lung disease, which is normally associated with smoking and is not associated with asbestos exposure. This is important because the population of persons exposed to asbestos includes a high percentage of smokers. A reduced FVC can be caused by either restrictive or obstructive lung disease. Additional findings help draw the distinction. When obstructive lung disease is present, the amount of air that can be expelled in the first second of a pulmonary function test falls faster than the amount that can be exhaled in the entire test. As a result, a low ratio of FEV1 (the amount of air that can be exhaled in the first second of the test) to FVC (the total amount of air exhaled during the test) indicates obstructive, rather than restrictive, lung disease. An FEV1/FVC ratio that is within normal limits is consistent with restrictive disease, assuming other tests of restrictive disease are also met, because the amount of air expelled in the first second does not fall faster than the total amount of air that can be expelled. Thus, the criteria adopt a commonly used measure that requires the FEV1/FVC ratio to be above the lower limit of normal, in order to exclude cases where the impairment is obstructive rather than restrictive.

**Total Lung Capacity:** The most accurate method of determining restrictive impairment is Total Lung Capacity ("TLC"). Restrictive lung disease (which can be asbestos-related) reduces the total capacity of the lung, while obstructive disease (usually associated with smoking) usually does not. Thus, a TLC below the lower limit of normal is indicative of restrictive disease but not obstructive disease. Many doctors believe TLC's are more

accurate in screening out obstructive cases than FVC in conjunction with the FEV1/FVC ratio discussed above, which can result in “false positives” – findings of restriction in individuals that do not have it. However, TLC tests can be slightly more costly and less widely available than the other tests described above, and the Standard developed by the Commission does not require them, notwithstanding that they may be the best evidence of restrictive impairment. Rather, in keeping with the ABA’s goal of being overly inclusive rather than unduly strict, the Standard allows claimants to meet the impairment definition through the use of either FVC with the FEV1/FVC ratio or TLC test results.

Paragraph 4c (“Backstop” provision): There were additional pulmonary function findings suggested by one or more of the doctors as possible ways to identify asbestos-related restriction in individuals who have other unrelated lung problems, such as chronic obstructive pulmonary disease. Other doctors rejected these suggested findings as unreliable, non-specific, or otherwise inappropriate. Rather than attempt to resolve these disputes, the Commission drafted a provision (paragraph 4c) that would allow claimants to file suit even if they fail to meet the criteria set forth in paragraphs 4a) or 4b).

The overwhelming majority of persons who are functionally impaired as a result of non-malignant asbestos disease would meet the criteria of either paragraph 4a) or 4b). However, it is possible that in unusual cases, some legitimate claim might be excluded. The Commission felt it inappropriate to draft the general Standard based on these rare cases. Instead, the Commission adopted a “backstop” provision so that in cases of clear interstitial fibrosis (defined in the Standard as a person whose x-ray grades at 2/1 or higher under the ILO system), a treating physician’s detailed opinion that the person suffers from restrictive impairment due to asbestosis is sufficient to allow the claimant to proceed.

### C. Medical Report and Diagnosis

The ABA heard extensive evidence, some of which is discussed above, that the huge increase in claims from unimpaired claimants is caused by litigation screenings that do not comply with generally accepted clinical standards. In many cases, claimants are not seen by a licensed physician and no medical “diagnosis” has been made. The Commission believes that cases of abuse will be minimized if true medical standards are observed. In addition to the requirement discussed above that PFT tests meet ATS standards and that supporting documentation be filed with the complaint, the Commission’s proposed criteria require a detailed narrative Medical Report and Diagnosis signed by the diagnosing doctor. The Commission believes that such a requirement will dramatically enhance the integrity of the process by requiring that a licensed physician take responsibility for the diagnosis. Similar requirements exist today in many state statutes relating to medical malpractice and have helped to raise the standard for filing such cases. The Commission believes that the indisputable impact of for-profit litigation screenings that lack appropriate medical oversight justifies the simple requirement proposed in the Commission’s criteria. The Commission believes that the

integrity of the physician community, perhaps even more than the tests described above, is a key safeguard against the abuses that have been prevalent in the asbestos litigation.

#### Recommended Changes to the Statute of limitations

The ABA strongly believes that it would be unfair to require that claimants wait to file suit until they develop the level of functional impairment required by the Standard, if a statute of limitations could simultaneously be running against them. Thus, in any legislation deferring asbestos-related claims involving no functional impairment, the ABA recommends that there be a concomitant provision tolling any otherwise applicable statute of limitations until the required level of diagnosis is met. No other changes in state statutes of limitations are proposed.

#### IV. Conclusion

The ABA believes that the flood of asbestos cases fully justifies limited Federal intervention with respect to statutes of limitation and impairment criteria. We urge enactment of federal legislation that would: 1) allow those alleging non-malignant asbestos-related disease claims to file a cause of action in state or federal court only if they meet the medical criteria in the "ABA Standard For Non-Malignant Asbestos-Related Disease Claims" dated February 2003 (which should be updated periodically in accordance with medical advances and scientific research) or an appropriate similar medical standard; and 2) toll all applicable statutes of limitations until such time as the medical criteria in such standard are met. However, the ABA has not addressed broader legislative solutions that have been discussed by others.

The ABA believes that any asbestos legislation should infringe on state law only to the extent necessary to achieve the goal of ensuring that the justice system operates to compensate those who are injured by asbestos equitably. As mentioned earlier, with few exceptions, the American Bar Association has long and consistently opposed the enactment of federal legislation that would attempt to create a national body of tort law that would apply in the fifty state justice systems. In addition to the February 1981 and February 1983 policies discussed earlier in this report, the ABA has adopted numerous other policies over the years that oppose the federalization of the tort laws in a host of areas. It has been the ABA's position that the state courts and legislatures are normally the appropriate bodies to develop product liability laws and that, except in discrete circumstances, Congress should not substitute its judgment for systems that have evolved in each state. A national solution is required because asbestos litigation presents unique challenges for this country's civil justice system and I believe the ABA's resolution adopted by our House of Delegates last month accomplishes this goal.

The ABA's resolution does not propose to create original federal jurisdiction for the prosecution of asbestos claims to the extent that such jurisdiction does not currently exist.

Thank you for giving me this opportunity to present to you the views of the ABA on this most important issue.

APPENDIX A

RESOLUTION ADOPTED BY THE

HOUSE OF DELEGATES

OF THE

AMERICAN BAR ASSOCIATION

FEBRUARY 2003

RESOLVED, That the American Bar Association supports enactment of federal legislation that would: 1) allow those alleging non-malignant asbestos-related disease claims to file a cause of action in state or federal court only if they meet the medical criteria in the "ABA Standard For Non-Malignant Asbestos-Related Disease Claims" dated February 2003 (which the House will be requested to update periodically in accordance with medical advances and scientific research) or an appropriate similar medical standard; and 2) toll all applicable statutes of limitations until such time as the medical criteria in such standard are met.

FURTHER RESOLVED, That the American Bar Association does not support limitations on the filing of claims for asbestos-related malignancies.

FURTHER RESOLVED, That the American Bar Association does not support the preemption of legal definitions for claiming or impairment as they may be found in regulations relating to the Longshore and Harbor Workers' Compensation Act (LHWCA), 33 U.S.C. §§901-50, Federal Employees' Compensation Act (FECA), 5 U.S.C. §§8101 et. seq., Energy Employees Occupational Illness Compensation Program Act, 42 U.S.C. §§7384-7385, Occupational Safety and Health Administration (OSHA), the Americans with Disabilities Act, the federal Rehabilitation Act, their state, territorial and local counterparts, Workers Compensation statutes in the 50 states, the District of Columbia, the Commonwealth of Puerto Rico and the insular territories and their regulations, and federal, state and territorial laws regulating employee benefit plans and employer health care coverage plans.

APPENDIX B

ABA Standard For Non-Malignant Asbestos-Related Disease Claims  
February 2003

I. The filing of any civil action alleging personal injury for asbestos related non-malignant

disease must be accompanied by a detailed narrative Medical Report and Diagnosis signed by the diagnosing doctor, that:

1. Verifies that the doctor or a medical professional employed by and under the direct supervision and control of the diagnosing doctor has taken:
  - a. A detailed occupational and exposure history from the person (“claimant”) whose alleged injury forms the basis for the action or, if that person is deceased, from the person most knowledgeable about the exposures that form the basis for the action. The history shall include all of the principal employments and exposures of the claimant involving exposures to airborne contaminants. It should indicate whether each employment involved exposure to airborne contaminants (including, but not limited to, asbestos fibers, and other disease causing dusts) that can cause pulmonary impairment and the nature, duration, and level of any such exposure; and
  - b. A detailed medical and smoking history that includes a thorough review of claimant’s past and present medical problems, and their most probable cause.
2. Sets out the details of the occupational, medical and smoking history, and verifies that at least 15 years have elapsed between the claimant’s first exposure to asbestos and the time of diagnosis.
3. Verifies that the claimant has:
  - a. A quality 1 chest x-ray taken in accordance with all applicable state and federal regulatory standards (in a death case where no pathology is available, the necessary radiologic findings may be made with a quality 2 film if a quality 1 film is not available), and that the x-ray has been read by a certified B-reader according to the ILO system of classification as showing bilateral small irregular opacities (s, t, or u) graded 1/0 or higher or bilateral diffuse pleural thickening graded b2 or higher including blunting of the costophrenic angle; or
  - b. Pathological asbestosis graded 1(B) or higher under the criteria published in the Asbestos-Associated Diseases, Special Issue of the Archives of Pathology and Laboratory Medicine, Volume 106, Number 11, Appendix 3 (October 8, 1982).
4. Verifies that the claimant has asbestos-related pulmonary impairment as demonstrated by Pulmonary Function Testing, performed using equipment, methods of calibration and technique that meet the criteria incorporated in the AMA Guides to the Evaluation of Permanent Impairment (5th Ed.) and reported as set forth in 20 CFR 404, Subpt. P, App 1, Part (A)§3.00 (E) and (F), and the interpretative standards set forth in the Official Statement of the American Thoracic Society entitled “Lung Function Testing: Selection of Reference Values And Interpretative Strategies” as published in Am. Rev. Resp. Dis. 1991:144:1202-1218 that shows:
  - a. Forced Vital Capacity below the lower limit of normal and FEV1/FVC ratio (using actual values) at or above the lower limit of normal; or

- c. Total Lung Capacity, by plethysmography or timed gas dilution, below the lower limit of normal.
- d. c. Where the Pulmonary Function Test results do not meet the requirements of (a) or (b), above, a claimant may submit an additional report, by a board certified pulmonologist, internist or occupational physician that states:

1. That the doctor has a doctor/patient relationship with the claimant; and

2) That the claimant has a quality 1 chest x-ray taken in accordance with all applicable state and federal regulatory standards (in a death case where no pathology is available, the necessary radiologic findings may be made with a quality 2 film if a quality 1 film is not available), and that the x-ray has been read by a certified B-reader according to the ILO system of classification as showing bilateral small irregular opacities (s, t, or u) graded 2/1 or higher; and

3) That the claimant has restrictive impairment from asbestosis and sets forth in detail the specific pulmonary function test findings that the doctor relies upon to establish that the claimant has restrictive impairment; and

4) That the physician shall submit the reports and readouts from all pulmonary function, lung volume, diffusing capacity or other testing relied upon for the report's conclusions. Such tests must comply with the equipment, quality and reporting standards set forth herein.

5. Verifies that the doctor has concluded that the claimant's medical findings and impairment were not more probably the result of other causes revealed by claimant's employment and medical history.

II. Copies of the B-reading, the pulmonary function tests (including printouts of the flow volume loops and all other elements required to demonstrate compliance with the equipment, quality, interpretation and reporting standards set forth herein) and the diagnosing physician's detailed narrative Medical Report and Diagnosis shall be attached to any complaint alleging non malignant, asbestos related disease. Failure to attach the required reports or demonstration by any party that the reports do not satisfy the standards set forth herein shall result in the dismissal of the action, without prejudice, upon motion of any party.

No state or federal statute of limitations governing personal injury tort actions arising from exposure to asbestos shall commence as a result of a purported diagnosis or finding of a non-malignant disease related to asbestos that does not meet the criteria set forth herein.